SNM hosts 55th Annual Meeting of Nuclear Medicine and Molecular Imaging Research

May 27, 2008

Reston, Va.--SNM's 55th Annual Meeting, "Molecular Imaging: Build on the Past, Define the Future," will be held June 14-18, 2008, at the Ernest N. Morial Convention Center, New Orleans, La., with more than 4,000 of the world's leading experts in molecular imaging and therapy and nuclear medicine attending.

New research expected to be unveiled in the molecular imaging, neurology, cardiology and oncology fields has the potential to directly affect the future of patient care. Notable topics to be discussed include the use of PET, SPECT and other forms of imaging to: A press conference will be held Monday, June 16, from 11:30 a.m.-12:30 p.m., to discuss specific research topics. During the press conference, Dr. Henry Wagner, Johns Hopkins University, will reveal the highly anticipated "SNM Image of the Year." Other portions of the annual meeting open to media include plenary sessions, categorical seminars, the exhibit hall and presentations of scientific papers and posters.

For more information about--and to register for--the SNM 55th Annual Meeting, visit www.snm.org/am.
-end-
ABOUT SNM--ADVANCING MOLECULAR IMAGING AND THERAPY

SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients, SNM members have introduced--and continue to explore--biological and technological innovations in medicine that non-invasively investigate the molecular basis of diseases, benefiting countless generations of patients. For more information, visit www.snm.org.

Society of Nuclear Medicine

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.